论文部分内容阅读
目的探讨131碘治疗和加用地塞米松治疗Graves病的临床疗效。方法将符合入选条件的98例Graves病患者随机分成研究组和对照组。从临床症状和体征、甲状腺功能(TT3、TT4、TSH)、临床控制率、基础代谢率等方面观察地塞米松配合131碘对Graves病的治疗效果。进行自身前后对照和组间两两比较。结果治疗后1周,研究组患者TT3水平较治疗前明显下降(P<0.01),TT4较治疗前有明显下降(P<0.01),基础代谢率较治疗前有明显下降(P<0.01),两组患者治疗前后血清TT3、TT4及基础代谢率差值比较差异有统计学意义(P<0.01)。结论地塞米松加131碘治疗Graves病疗效满意,能较快的改善自觉症状,减少早期并发症,预防Graves病危象发生。
Objective To investigate the clinical efficacy of 131 iodine and dexamethasone in the treatment of Graves’ disease. Methods A total of 98 patients with Graves’ disease who were eligible for inclusion were randomly divided into study group and control group. The therapeutic effects of dexamethasone and 131 iodine on Graves’ disease were observed from clinical symptoms and signs, thyroid function (TT3, TT4, TSH), clinical control rate and basal metabolic rate. Before and after their own control and comparison between groups. Results One week after treatment, the TT3 level in study group decreased significantly (P <0.01), TT4 level decreased significantly (P <0.01), and basal metabolic rate decreased significantly (P <0.01) The difference of serum TT3, TT4 and basal metabolic rate between the two groups before and after treatment was statistically significant (P <0.01). Conclusion Dexamethasone plus 131 iodine is effective in treating Graves ’disease, which can improve the symptoms more quickly, reduce the early complications and prevent the occurrence of Graves’ disease.